YRYuefeng Rao

Yuefeng Rao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuefeng Rao has a total of 129 co-authors. Here are the top co-authors by number of shared publications:

  • Yun Hong

    The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    5 shared publications
  • Ziqi Ye

    Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

    5 shared publications
  • Ziqi Ye

    Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, China

    5 shared publications
  • Feiyue Zheng

    Department of Pharmacy, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China

    4 shared publications
  • Hongyu Yang

    Department of Pharmacology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

    4 shared publications
  • Xiuhua Wu

    Department of Pharmacology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

    4 shared publications

Latest Publications

  • Open Access

    Consensus on the Clinical Use of Pregabalin in Peripheral Neuropathic Pain

    by Hui Lu, Yuefeng Rao, Jian Wang, Wan Shuanglin, Du Dongping, Ma Ke, Zhiying Feng, Suming Tian, Weidong Qiu, Xu Jing, et al.

    Background: Peripheral neuropathic pain (pNP) is a prevalent and complex clinical condition that presents significant therapeutic challenges, with pharmacological options demonstrating variable efficacy and safety. Objective: To establish expert consensus recommendations on the clinical use of pregabalin in the management of diverse pNP conditions. Methods: A multidisciplinary panel of Chinese experts from orthopedics, pain management, neurology, oncology, dermatology, and pharmacy conducted a comprehensive literature review and synthesized clinical evidence to formulate consensus‐based recommendations. Results: Pregabalin, a second‐generation calcium channel regulator, demonstrated broad efficacy across multiple pNP conditions, including postherpetic neuralgia (PHN), diabetic peripheral neuropathy (DPN), neuropathic cancer pain (NCP), postoperative and post‐traumatic neuralgia, and trigeminal neuralgia (TN). In PHN, pregabalin significantly reduced pain intensity and improved sleep quality. In DPN, it provided consistent analgesia with improved pain scores and good tolerability. In NCP, pregabalin effectively alleviated pain, showed no significant drug–drug interactions, and was safely co‐administered with chemotherapy. It was also effective in postoperative and post‐traumatic neuralgia, although caution is warranted in cases of traumatic neuroma. In TN, pregabalin exhibited favorable low‐dose efficacy, particularly in elderly patients, with minimal adverse effects. However, cautious use is advised in patients with nerve compression syndromes, such as carpal tunnel syndrome, and in individuals with a history of substance abuse. Conclusions: This consensus highlights pregabalin as an effective and generally well‐tolerated therapeutic option for a broad range of pNP conditions. These recommendations provide clinically relevant guidance for optimizing pregabalin use, particularly within the Chinese healthcare context.


  • Open Access

    Efficacy and safety of National Centralized Drug Procurement-procured versus non-National Centralized Drug Procurement oxaliplatin in unresectable or metastatic pancreatic cancer: a retrospective cohort study

    by Ziqi Ye, Linlin Yang, Yanfang Zhang, Xiaoting Wang, Yuefeng Rao

    Background: China’s National Centralized Drug Procurement (NCDP) policy has substantially reduced the cost of essential medicines, yet concerns persist regarding the real-world therapeutic equivalence of NCDP-procured drugs compared to their non-NCDP counterparts. This study aimed to systematically evaluate, using real-world data, the comparative efficacy and safety of NCDP-procured versus non-NCDP oxaliplatin in patients with advanced pancreatic cancer. Methods: This single-center retrospective cohort study enrolled patients with unresectable or metastatic pancreatic cancer who received first-line mFOLFIRINOX between May 2022 and March 2025. Patients were stratified into NCDP and non-NCDP groups based on the procurement source of oxaliplatin. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Safety was assessed by the incidence of adverse drug reactions (ADRs). Results: Among 168 enrolled patients (NCDP, n=77; non-NCDP, n=91), no significant between-group differences were observed in ORR (9.1% vs. 13.2%, P=0.47), disease control rate (57.1% vs. 63.7%, P=0.43), or median PFS [6.5 vs. 6.0 months; adjusted hazard ratio (HR) =1.034, 95% confidence interval (CI): 0.691–1.547, P=0.87]. However, the NCDP group exhibited significantly lower incidences of elevated aspartate aminotransferase (AST) (28.6% vs. 45.1%, P=0.04) and grade ≥3 anemia (2.6% vs. 15.4%, P=0.007), which remained significant after multivariable adjustment. After propensity score matching, baseline characteristics were well-balanced between groups (all P>0.10), and the primary findings remained consistent. The unit price of NCDP oxaliplatin (¥ 76/vial) was 45% of the price of the non-NCDP agent (¥ 170/vial), representing substantial cost savings. Conclusions: NCDP-procured oxaliplatin demonstrated comparable efficacy to non-NCDP alternatives in advanced pancreatic cancer, with a more favorable safety profile for specific hepatic and hematologic toxicities. These real-world findings support the translation of the national procurement policy into clinical practice, offering significant cost savings without compromising patient outcomes.


  • Effect of Immune Thrombocytopenic Purpura Medications on Depression Risk: An Analysis of NHANES Data

    by Feiyue Zheng, Zhengwei Yu, Zhang Zhang, Jinli Miao, Wenmin Wang, Jiaying Wu, Yuefeng Rao

    Background: Immune thrombocytopenic purpura (ITP) in adults typically develops slowly and insidiously. The ITP medications might be linked to psychological disorders, but the connection is not well-understood. Objective: This study aimed to examine the association between ITP medication use and the risk of depression among participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2018. Methods: Using data from 70 190 NHANES participants, we conducted a cross-sectional study, excluding individuals under 18 years, with hypertension, HIV, hepatitis C, and various comorbidities. A total of 17 299 individuals were included in the analysis of this study. We identified 2 populations within this study: those using ITP medications, including prednisone, dexamethasone, and rituximab and those not using ITP drugs. Depression status was assessed using the Patient Health Questionnaire–9 (PHQ-9), and the relationship between ITP medication use and depression was analyzed through multivariate logistic regression. Results: There was no significant association between ITP medication use and an increased risk of depression after adjusting for demographic and health-related variables. Notably, among the study participants, 1.8% of the non-depressed population were on ITP medication compared with 0.3% in the depressed population. The analysis revealed varying depression risks associated with different sociodemographic factors. For instance, the correlation between ITP medication and depression risk was influenced by a combination of age, race, income, and smoking status. Conclusion and Relevance: The study suggests that ITP medication use does not independently increase the risk of depression. This finding is crucial for guiding clinical decisions and managing patient expectations regarding ITP treatment and its psychological impacts.


  • Open Access

    Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice

    by Xing Hao, Yiting Zhou, Yingxian Ling, Hirotsugu Miyoshi, Masahiko Sumitani, Kwok Ying Chan, Hue Jung Park, Zhiying Feng, Yuefeng Rao

    Original Article Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice Xing Hao, Yiting Zhou, Yingxian Ling, Hirotsugu Miyoshi, Masahiko Sumitani, Kwok Ying Chan, Hue Jung Park, Zhiying Feng, Yuefeng Rao


  • Open Access

    Population pharmacokinetics of polymyxin B: a systematic review

    by Na Chen, Jianhao Guo, Jiao Xie, Mi Xu, Xing Hao, Kuifen Ma, Yuefeng Rao

    Background: Polymyxin B (PMB) is a basic cyclic polypeptide antibiotic produced by Bacillus polymyxa, and is one of the last options for treating multi-drug-resistant negative bacterial infections in clinical practice. In recent years, many population pharmacokinetic studies of PMB have been conducted. This paper sought to comprehensively summarize the characteristics of population pharmacokinetic models of PMB and provide a theoretical basis for the individualized use of PMB. Methods: In this review, we systematically searched the PubMed and Embase databases to find articles on population pharmacokinetic models published from database establishment to August 2021. Results: A total of 10 studies were included in this review, including studies on various types of severe infections caused by multi-drug-resistant bacteria, hospital-acquired infections with fibrosis and other male and female populations, and a study of 2 continuous renal replacement therapy (CRRT) patients, aged 16–94 years, who received PMB doses of 10–360 mg/day (0.13–3.45 mg/kg/day), at an administration time of 0.5–6 hours. First-order linear elimination was used in all the studies; a 1-compartment model was used in 5 studies, and a 2-compartment model was used in 5 studies. The most common covariates were creatinine clearance (CrCL) and body weight. Discussion: Although these studies included several covariates and total clearance (CL) was close, but the external validation of some models was poorly correlated between the actual and predicted value. Novel or potential covariates represent important directions for further study.


  • Open Access

    Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series

    by Jun Li, Kuifen Ma, Liangping Wang, Huaji Qi, Junhao Lv, Yuefeng Rao, Wenhan Peng

    Background: To observe the efficacy and safety of roxadustat, an inhibitor of proline hydroxylase, in renal allograft anemia patients. Methods: This prospective study collected the clinical data of renal transplant patients treated with roxadustat for anemia at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University from April to August 2020. The patients were followed up every 2 weeks, and the changes in their hemoglobin index and any adverse reactions were recorded during 10 weeks of treatment. The efficacy of roxadustat for treatment of anemia after kidney transplantation was analyzed by comparing the change and increase in average hemoglobin levels before and after treatment. Rates of treatment response and achievement of the standard hemoglobin level were statistically analyzed. In addition, any potential adverse events and the glomerular filtration rate were recorded for 10 weeks to assess the safety of roxadustat in renal allograft anemia patients. Results: After 10 weeks of roxadustat treatment, the mean hemoglobin level was 10.4±3.9 g/dL, which was significantly higher than at baseline. Over the entire period, treatment was observed to have a therapeutic effect at weeks 2–4, with mean hemoglobin levels increasing as treatment time increased. At the 10-week endpoint, the percentage of patients reaching the standard hemoglobin level and exhibiting a response to treatment was 52.4% and 71.4%, respectively. During the treatment, there was no rejection, and the glomerular filtration rate was stable. Only one person showed symptoms of fatigue, and there were no other obvious adverse reactions reported. Conclusions: Roxadustat significantly improves hemoglobin levels and can be safely used in renal transplant anemia patients.


  • Open Access

    Reliability and validity of a modified 8-item Morisky Medication Adherence Scale in patients with chronic pain

    by Yanfeng Zhang, Rongrong Wang, Qiming Chen, Sizhe Dong, Xuejiao Guo, Zhiying Feng, Yuefeng Rao

    Background: The 8-item Morisky Medication Adherence Scale (MMAS-8) is a simple, economic and easy tool to evaluate the medication compliance of chronic disease. The reliability and validity of the MMAS-8 in patients with chronic pain were unclear. Therefore, we aimed to validate the MMAS-8 for detecting nonadherent patients with chronic pain. Methods: A modified MMAS-8 was used to assess the medication compliance of patients with chronic pain who were treated at our hospital from July 2018 to October 2018. Cronbach’s α was used to evaluate the internal consistency, and a factor analysis was used to examine the construct validity. Convergent validity was assessed by comparing the MMAS-8 and a medication adherence visual analog score (MA-VAS) through Pearson’s correlation coefficient. Results: A total of 113 patients were evaluated. The (t-test) results revealed that there was a significant difference in average scores between the low-score group (who scored less than 5 points) and the high-score group (who scored 8 points or above), indicating that the scale displayed a good degree of discrimination. Except for Items 4 and 5, all the other items exhibited a good correlation with the total score (correlation coefficient >0.5; PConclusions: The modified MMAS-8 exhibited acceptable reliability and validity in evaluating medication compliance in patients with chronic pain; thus, it can be applied to detect nonadherent patients with chronic pain.


  • Open Access

    Continuous improvement on the rationality of prophylactic injectable PPIs usage by a clinical pharmacist-led guidance team at a Chinese tertiary teaching hospital

    by Yun Hong, Ziqi Ye, Zhe Gao, Yuefeng Rao

    Objective: We aimed to evaluate the effects of a clinical pharmacist-led-guidance-team (CPGT) on improving rational prophylactic injectable proton pump inhibitor use (PIPU) and to explore the application of the Plan–Do–Check–Act (PDCA) method in promoting rational PIPU. Methods: We conducted a retrospective study among 814 patients at a Chinese tertiary teaching hospital from January 2017 to December 2018. We enrolled 98 patients before the PDCA; 297 and 419 patients were included in first- and second-round PDCA cycles, respectively. The CPGT established the criteria for PIPU and conducted interventions, including medical record reviews, provision of feedback, clinician education, and outcome analysis. We analyzed the appropriateness and costs of PIPU before and after establishment of the PDCA cycle. Results: Implementation of continuous CPGT-led intervention and a PDCA cycle significantly decreased the rate of irrational PIPU (53.06% vs. 8.57%), including duration, administration route, indication, and dosing frequency. Costs of total (USD 211.28 ± 162.33 vs. 53.17 ± 22.32) and inappropriate (USD 76.70 ± 59.78 vs. 2.25 ± 3.86) PIPU per patient were significantly reduced. The target compliance rate was 107.56%. Conclusion: A CPGT can have an effective role in improving rational PIPU and optimizing administration through a PDCA cycle, to attain improved clinical and economic outcomes.


  • Open Access

    Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

    by Haiying Ding, Wenxiu Xin, Yinghui Tong, Jiao Sun, Gaoqi Xu, Ziqi Ye, Yuefeng Rao

    Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs. The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC). We searched the PubMed, Web of Science, and Cochrane Library for studies comparing the cost effectiveness of ICIs for NSCLC. Potential studies identified were independently checked for eligibility by two authors, with disagreement resolved by a third reviewer. Quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards checklists. A total of 22 economic studies were included. Overall reporting of the identified studies largely met CHEERS recommendations. In the first-line setting, for advanced or metastatic NSCLC patients with PD-L1 ≥ 50%, pembrolizumab appeared cost-effective compared with platinum-based chemotherapy in the US and Hong Kong (China), but not in the UK and China. The cost-effectiveness of pembrolizumab versus chemotherapy for first-line treatment of NSCLC in PD-L1 ≥ 1% patients remained obscure. Regardless of PD-L1 expression status, pembrolizumab in combination with chemotherapy could be a cost-effective first-line therapy in the US. On the contrary, addition of atezolizumab to the combination of bevacizumab and chemotherapy was not cost-effective for patients with metastatic non-squamous NSCLC from the US payer perspective. In the second-line setting compared with docetaxel, pembrolizumab was cost-effective; though nivolumab was not cost-effective in the base case, it could be by increased PD-L1 threshold. Results of the cost-effectiveness of atezolizumab second-line treatment remained inconsistent. In addition, the adoption of durvalumab consolidation therapy after chemoradiotherapy could be cost-effective versus no consolidation therapy for patients with stage III NSCLC. Immunotherapy can be a cost-effective option for treatment of NSCLC in several scenarios. A discount of the agents or the use of PD-L1 expression as a biomarker improves the cost-effectiveness of immunotherapy.